Table 2 Characteristics and laboratory values of case and control patients among Molecular-targeted drug users (Univariate Analysis).

From: Predictors of chemotherapy-related unplanned acute care in outpatients receiving oral anticancer drugs

Characteristics

Case group (n = 75)

Control group (n = 196)

Odds ratio

(95% CI)

p-value

Laboratory variables

Case group

(n = 75)

Control group

(n = 196)

Odds ratio

(95% CI)

p-value

n

%

n

%

Age (mean ± SD)

67.1 ± 10.5

 

67.8 ± 9.4

 

0.99 (0.97–1.02)

0.59

TP (g/dL)

6.8 ± 0.6

6.9 ± 0.5

0.77 (0.47–1.27)

0.31

Sex

ALB (g/dL)

3.7 ± 0.5

3.9 ± 0.4

0.51 (0.28–0.92)

0.03*

 Male

26

34.7

70

35.7

1.00 (ref)

0.87

GLU (mg/dL)

119.7 ± 36.3

112.6 ± 30.5

1.01 (0.99–1.01)

0.11†

 Female

49

65.3

126

64.3

1.05 (0.6–1.83)

UN (mg/dL)

16.6 ± 8.3

15.6 ± 4.6

1.03 (0.98–1.07)

0.22

BMI (mean ± SD)

22.6 ± 4.1

 

22.4 ± 3.7

 

1.02 (0.95–1.09)

0.60

CRE (mg/dL)

0.9 ± 0.4

0.8 ± 0.2

2.57 (1.06–6.25)

0.04*

Cancer Type

eGFR (mL/min/1.73 m²)

62.3 ± 20.7

64.6 ± 17.2

0.99 (0.98–1.01)

0.35

 Lung cancer

38

50.7

106

54.1

1.00 (ref)

 

Na (mmol/L)

141.0 ± 2.9

141.4 ± 2.7

0.96 (0.87–1.06)

0.40

 Colorectal cancer

6

8.0

20

10.2

0.84 (0.31–2.24)

0.72

K (mmol/L)

4.1 ± 0.4

4.1 ± 0.3

1.16 (0.56–2.43)

0.69

 Breast cancer

12

16.0

25

12.8

1.34 (0.61–2.93)

0.46

Cl (mmol/L)

104.5 ± 2.8

104.7 ± 3.2

0.99 (0.91–1.08)

0.77

 Other

19

25.3

45

23.0

1.18 (0.61–2.26)

0.62

Ca (mg/dL)

8.9 ± 0.5

9.0 ± 0.4

0.63 (0.35–1.15)

0.13†

Performance Status

AST (U/L)

42.1 ± 89.1

27.6 ± 14.3

1.01 (0.99–1.03)

0.07†

 0

35

46.7

96

49.0

1.00 (ref)

 

ALT (U/L)

42.4 ± 140.1

22.3 ± 20.9

1.01 (0.99–1.02)

0.18†

 1

32

42.7

84

42.9

1.04 (0.56–1.83)

0.88

γ–GTP (U/L)

54.8 ± 97.6

49.7 ± 74.7

1.00 (0.99–1.00)

0.65

 2

8

10.7

25

7.7

1.46 (0.57–3.75)

0.43

T-Bil (mg/dL)

0.7 ± 0.5

0.7 ± 0.4

1.25 (0.67–2.31)

0.48

 3

-

-

1

0.5

-

-

ALP (U/L)

278.6 ± 253.8

246.4 ± 160.4

1.00 (0.99–1.00)

0.23

 4

-

-

-

-

-

-

LDH (U/L)

261.1 ± 131.6

230.2 ± 131.5

1.00 (1.00–1.00)

0.11†

Treatment setting

CRP (mg/dL)

1.6 ± 4.3

0.6 ± 1.2

1.16 (1.02–1.32)

0.02*

 Progression/recurrence

74

98.7

195

99.5

1.00 (ref)

0.50

RBC (10 4/µ L)

393.5 ± 77.6

401.5 ± 61.4

0.99 (0.99–1.00)

0.38

 Cure (adjuvant/neoadjuvant)

1

1.3

1

0.5

2.64 (0.16–42.70)

Hb (g/dL)

12.0 ± 2.0

12.4 ± 1.7

0.88 (0.76–1.03)

0.10†

Treatment line

Plt (10 4/µ L)

20.2 ± 9.2

18.4 ± 6.3

1.03 (0.99–1.07)

0.07†

 1st

35

46.7

68

34.7

1.00 (ref)

0.07†

WBC (10 2/µ L)

54.0 ± 23.7

49.9 ± 18.3

1.01 (0.99–1.02)

0.13†

 ≥ 2nd

40

53.3

128

65.3

0.61 (0.35–1.04)

Neut (10 2/µ L)

35.7 ± 19.6

32.1 ± 15.6

1.01 (0.99–1.03)

0.12†

Treatment classification

Lymp (10 2/µ L)

12.4 ± 5.8

12.6 ± 5.1

0.99 (0.95–1.05)

0.85

 Monotherapy

70

93.3

183

93.4

1.00 (ref)

0.99

Mono (10 2/µ L)

3.9 ± 2.1

3.5 ± 1.5

1.14 (0.98–1.33)

0.09†

 Injection combination therapy

5

6.7

13

6.6

1.01 (0.35–2.92)

 
  1. Crude odds ratios for continuous variables indicate an association with a 1-unit increase.
  2. †p < 0.2, *p < 0.05.
  3. UAC: Unplanned acute care; BMI: Body mass index; TP: total protein; ALB: albumin; GLU: blood glucose; UN: blood urea nitrogen; CRE: creatinine; eGFR: estimated glomerular filtration rate; AST: aspartate aminotransferase; ALT: alanine aminotransferase; Îł-GTP: Îł-glutamyl transpeptidase; T-Bil: total bilirubin; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; CRP: C-reactive protein; RBC: red blood cell; Hb: hemoglobin; Plt: platelet; WBC: white blood cell; Neut: neutrophil; Lymp: lymphocyte; Mono: monocyte.
Back to article page